Loading
A phase 1/2 trial of XZP-3287 and Fulvestrant in advanced solid tumours, run by Sihuan Pharmaceutical Holdings Group Ltd., active and no longer recruiting.
A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors is a phase 1/2 interventional study registered as NCT04539496 by Sihuan Pharmaceutical Holdings Group Ltd., with 402 participants enrolled, started 2018-05-22 and due to reach its primary completion in 2023-07-31. Interventions recorded: XZP-3287 and XZP-3287;Letrozole;Anastrozole;Fulvestrant.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares XZP-3287, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/